Compare EYPT & ENVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EYPT | ENVX |
|---|---|---|
| Founded | 1987 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Industrial Machinery/Components |
| Sector | Industrials | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2005 | 2020 |
| Metric | EYPT | ENVX |
|---|---|---|
| Price | $12.55 | $6.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $31.80 | $13.61 |
| AVG Volume (30 Days) | 941.4K | ★ 8.1M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.94 |
| EPS | N/A | ★ N/A |
| Revenue | $7,539,000.00 | ★ $31,821,000.00 |
| Revenue This Year | N/A | $30.37 |
| Revenue Next Year | $3,115.57 | $238.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 37.91 |
| 52 Week Low | $8.37 | $4.67 |
| 52 Week High | $19.11 | $16.49 |
| Indicator | EYPT | ENVX |
|---|---|---|
| Relative Strength Index (RSI) | 48.33 | 44.58 |
| Support Level | $12.58 | $6.40 |
| Resistance Level | $14.73 | $8.86 |
| Average True Range (ATR) | 0.75 | 0.74 |
| MACD | -0.02 | -0.17 |
| Stochastic Oscillator | 48.53 | 12.14 |
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, the United States, Norway, Taiwan, and other regions.